Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Hologic, Inc. (NASDAQ: HOLX ) in the spotlight. It is my first deeper dive into this large diagnostic concern since my article on it back in November 2023. Th ...

Shares of Hologic (HOLX) recorded a new 52-week low of $69.46 during Monday’s trading before finishing slightly higher at $70.29. Yesterday, the stock ended at $70.20, marking the lowest close in recent sessions. The latest drop in the share price can be attributed to the company’s mixed preliminary revenue results for the fiscal 2025 first quarter, released earlier this week.In the past six months, Hologic shares have dipped 12%, steeper than the industry’s 0.6% fall and the broader market’s 11.1% decline. ...

Exhibit 99.1 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025 – Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance – – GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges – MARLBOROUGH, Mass. (January 12, 2025) – Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approxima ...

The most recent trading session ended with Hologic (HOLX) standing at $72.73, reflecting a +0.05% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq decreased by 0.06%.Coming into today, shares of the medical device maker had lost 5.39% in the past month. In that same time, the Medical sector lost 5.77%, while the S&P 500 lost 2.8%.The upcoming earnings ...

Hologic, Inc. (HOLX) announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions for women’s health. Hologic acquired Gynesonics for approximately $350 million. The latest acquisition is aimed at strengthening Hologic’s GYN Surgical business segment.Likely Trend of HOLX Stock Following the NewsFollowing the announcement, shares of the company surged 0.8% to $73.77 yesterday.The transform ...

Hologic (HOLX) closed at $72.68 in the latest trading session, marking no change from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq lost 0.05%.Heading into today, shares of the medical device maker had lost 8.51% over the past month, lagging the Medical sector's loss of 4.31% and the S&P 500's gain of 1.05% in that time.The investment community will be paying close attention to the earnings performance ...

Hologic, Inc. (HOLX) recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.The latest ...

Hologic (HOLX) closed at $70.76 in the latest trading session, marking a -0.99% move from the prior day. This change lagged the S&P 500's 0.09% loss on the day. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.1%.Prior to today's trading, shares of the medical device maker had lost 8.42% over the past month. This has lagged the Medical sector's loss of 2.1% and the S&P 500's loss of 0.29% in that time.Investors will be eagerly watching for the performance of Hologic in its upcoming earnin ...

Hologic (HOLX) is currently trading at a forward price-to-earnings (P/E) multiple of 17.62X, well below the industry average of 32.42X. The company, specializing in medical devices for women’s health, also stands out with respect to industry peers Globus Medical (GMED) and Masimo (MASI) , which trade at a higher P/E of 24.25X and 39.01X, respectively. Hologic currently has a Value Score of B.Price-to-Earnings Forward Twelve Months (F12M)Image Source: Zacks Investment ResearchYesterday, HOLX stock ended the ...

On Sunday, Hologic (HOLX) presented new research evaluating the performance of its Genius AI Detection 2.0 software across diverse patient populations at the 110 Scientific Assembly and Annual Meeting of the Radiological Society of North America ("RSNA"). The research, titled "Performance of a Digital Breast Tomosynthesis AI Detection Algorithm in Common U.S. Racial/Ethnic Groups," revealed that the measured performance of the algorithm was similar across all evaluated cohorts. Hologic is also introducing i ...